Nkgen Biotech, INC Form 4 insider transactions

CFIC-2015 NV Family Investments, LLC, a 10% owner and entity controlled by directors Andrew and Peggy Cherng, has acquired over 19.6 million shares and received warrants for an additional 39.3 million shares of NKGen Biotech, Inc. common stock.

NKGen Biotech's CEO, Paul Y. Song, recently acquired shares and warrants of the company's common stock.

Graf Acquisition Partners IV LLC distributed shares and warrants of NKGen Biotech to its members following the one-year anniversary of the business combination.

Graf Acquisition Partners IV LLC, a significant shareholder of NKGen Biotech, Inc., reported the distribution of common stock, private placement warrants, and working capital warrants to its members.

Kathleen D. Scott, a director at NKGen Biotech, was granted stock options for 800,000 shares on December 6, 2024, under the company's 2023 Equity Incentive Plan.

NKGen Biotech granted Michael Klowden a total of 800,000 stock options on December 6, 2024, under the company's 2023 Equity Incentive Plan.

NKGen Biotech's CEO, Paul Y. Song, was granted 2 million stock options under the company's 2023 Equity Incentive Plan.

NKGen Biotech's Chief Financial Officer, James A. Graf, was granted 500,000 stock options under the company's 2023 Equity Incentive Plan.

Marco Gottardis, a director at NKGen Biotech, granted power of attorney for SEC filings and received 300,000 stock options.